ClinicalTrials.gg
WithdrawnNCT04384679Updated Aug 23, 2022

Benefit of Topical Hemostatic Powder Containing Hydrophilic Polymer With Potassium Ferrate for Hemostasis Following Nail Surgery

A Phase 4 interventional study of Hydrophilic polymer and potassium ferrate powder in Nail Diseases, sponsored by Weill Medical College of Cornell University. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-23.

Sponsored by Weill Medical College of Cornell University · Phase 4, Interventional, and Supportive care

Why this study was withdrawn
Due to reallocation of resources, this study could not be initiated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy and safety of topical hemostatic powder containing hydrophilic polymer with potassium ferrate for bleeding control after nail surgical procedures

02

Conditions studied

  • Nail Diseases

Keywords

  • Nails
  • Nail Surgery
  • Hemostasis
  • Potassium Ferrate
03

In context

Lead sponsor

Weill Medical College of Cornell University is the lead sponsor of 892 studies on the registry; 165 are open to participants now.

Of its 123 completed or terminated interventional studies of FDA-regulated products, 94 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years old
  • Patients scheduled for any type of nail surgical procedure
  • Willingness to participate in the study
  • Ability to understand all instructions in the English language

Exclusion criteria

Exclusion Criteria:

  • Failure to have nail surgery performed
  • Likely inability to comply with the study protocol or cooperate fully with the research team
05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Hydrophilic polymer and potassium ferrate powder

    Hydrophilic polymer with potassium ferrate powder is applied to the surgical wound with pressure until hemostasis is achieved

    Device: Hydrophilic polymer and potassium ferrate powder

  • No intervention
    Direct pressure with sterile gauze

    Direct pressure with sterile gauze is applied to the surgical wound until hemostasis is achieved

Interventions

  • DeviceHydrophilic polymer and potassium ferrate powder

    Application with pressure until hemostasis is achieved

06

What researchers measure

Primary outcomes

  1. Time (in seconds) to bleeding cessation with hydrophilic polymer and potassium ferrate; time (in seconds) to bleeding cessation with direct pressure with sterile gauze

    Time (in seconds) will be measured from application of intervention/nonintervention until bleeding cessation

    Time frame: Baseline

Secondary outcomes

  1. Number of participants with at least one adverse event

    Adverse events will only include those that are determined to be related to the study device

    Time frame: End of study (28 days)

07

Study locations

1 site
  • Weill Cornell Medicine
    New York, New York 10021, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2022; primary completion for Dec 2022, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2020
First posted
May 12, 2020
StartEst.
Jun 2022
Primary completionEst.
Dec 2022
CompletionEst.
Dec 2023
Last update
Aug 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04384679
Responsible party
Sponsor
First posted
May 12, 2020
Start date
Jun 2022 (estimated)
Primary completion
Dec 2022 (estimated)
Completion
Dec 2023 (estimated)
Last update
Aug 23, 2022

Study contacts

Shari R Lipner, MD, PhD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion